31 results about "Thrombotic risk" patented technology

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and / or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and / or atherosclerosis.

The invention discloses a low-blood-loss micro axial-flow type artificial heart which comprises a vane wheel, a motor rotor, and a motor stator, wherein the vane wheel is arranged inside the motor rotor in an interference fit and coaxial mode, the vane wheel is placed between an entry guide vane and an exit guide vane, two flow-guiding cones with large ends of 3mm are respectively arranged on an inlet end of the entry guide vane and an outlet end of the exit guide vane, the conical degree of the flow-guide cone is 90 degrees, and the two flow-guiding cones are in symmetrical arrangement. The helical angle of each flow-guiding vane on the entry guide vane gradually reduces from 90 degrees to 30 degrees along the axial direction from the inlet end to the outlet end, and the helical angle of each flow-guiding vane on the exit guide vane 3 gradually increases from 30 degrees to 90 degrees along the axial direction from the inlet end to the outlet end. The vanes on the vane wheel and all the flow-guiding vanes are in the shape of a logarithm helical line. Shaftless drive of the vane wheel reduces thrombus risk, and the micro structure improves the ability to implant. The low-blood-loss micro axial-flow type artificial heart has the advantages of being low in hemolysis, strong in implanting ability, simple in structure, high in reliability and the like.

The invention belongs to the field of medical apparatuses, and in particular relates to a vascular woven stent. The vascular woven stent comprises a woven stent main body and a coating, wherein the woven stent main body is constituted by metal wires having a shape memory function; and the coating comprises a drug coating bottom course and a protective top course. The vascular woven stent provided by the invention, by combining the woven stent, can effectively relieve coating falling, so that an acute thrombosis risk is reduced, stimulation to vascular walls and blood vessels is relieved, an occurrence rate of vascular restenosis is reduced, thrombogenesis is relieved, influence of patients' complications to the drug coating is relieved, and finally, product's effectiveness is improved.

The invention discloses a preparation method of a chitosan-agar oligosaccharide porous ball hemostatic material. The method comprises the following steps of: S1, preparing a chitosan-agar oligosaccharide compound solution; S2, adding a crosslinking agent 1,3-diepoxy glyceryl ether glycerinum into a compound alcohol solution, dropwise adding the chitosan-agar oligosaccharide compound solution into the compound alcohol solution containing the 1,3-diepoxy glyceryl ether glycerinum under the ultrasonic power of 130-150W, after dropwise addition, stopping ultrasonic treatment, and stirring the mixture for 30min at 600-800rpm; and S3, filtering balls, and washing, freezing and drying the balls. The hemostatic material prepared by the invention is good in biocompatibility and safe and non-toxic, can quickly accelerate blood clotting and has efficient hemostatic activity, has a certain volume, and is unlikely to enter blood to induce a thrombus risk. Meanwhile, the material has excellent wound adaptability, and is in particular suitable for bleed stopping of wounds which are deep, narrow and irregular. The preparation disclosed by the invention is simple in preparation process and easy for industrial production.

The invention discloses a medicament for preventing in-stent restenosis after coronary stent implantation and a preparation method. The medicament is prepared into 1000 parts from, by weight, 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of camphol and borneol and 6-9 parts of musk ketone. The medicament has the advantages of effective treatment, no toxic and side effects and capabilities of decreasing occurrence rate of in-stent restenosis after coronary stent implantation, obviously improving clinical symptoms of patients and reducing long-term risks of thrombosis of the patients, and is obvious in clinical effect. The medicament provides a new choice for preventing ISR (in-stent restenosis) after coronary stent implantation.

The invention discloses an ovarian malignant tumor patient thrombus risk prediction model modeling method and prediction device, and the modeling method comprises the steps: obtaining clinical examination data of a research object; taking whether venous thromboembolism occurs or not as a dependent variable, and establishing a logistic regression model by using the clinical examination data to obtain independent prediction factors of venous thromboembolism; and establishing a column graph according to the independent prediction factors. According to the modeling method and the prediction device, the risk of venous thromboembolism of the patient with the ovarian malignant tumor is predicted through the column diagram constructed by using the clinical examination data, and a quantitative prediction result with higher accuracy can be obtained.

The invention provides a pipe for preparing a stent and a preparation method thereof, a stent and a preparation method thereof. The outer layer of the pipe, the middle layer of the pipe and the inner layer of the pipe are sequentially arranged from outside to inside along the radial direction of the pipe, the outer layer of the pipe and the inner layer of the pipe are both composed of biodegradable polymers, and the middle layer of the pipe is composed of Woven from biodegradable fibers. The stent prepared from the tube of the present invention contains a biodegradable fiber braided structure, which can provide effective radial support force in large-diameter cavities, and the biodegradable fiber braided structure is wrapped in a degradable polymer, which can ensure The stent has good bending deformation properties, which enables the stent to be applied to various blood vessels, and reduces the risk of fatigue fracture caused by the expansion and contraction process of the stent after the stent is implanted in the blood vessel. Compared with the existing biodegradable polymer stent, the stent of the present invention has a thin wall, which facilitates the promotion of endothelialization and reduces the risk of thrombosis caused by stent implantation.

The invention discloses a double-compartment venous port access as well as a using method of venous transfusion and drug storage sustained release thereof. The venous port access comprises an infusioncatheter and a cylindrical access body which is formed by medical silica gel, wherein the access body comprises a cavity; two ends of the access body are of hemispherical structure; the cavity is provided with a diaphragm, so that the cavity is divided into two compartments; the diaphragm is provided with pores by which liquid can permeate; and the infusion catheter is connected to one end of theaccess body and communicates with one of the compartments. The method comprises the following steps: implanting the double-compartment venous port access into a human body; penetrating an intravenousinjection into the compartment which communicates with the infusion catheter and conducting infusion; penetrating a fine-needle syringe into the other compartment of the venous port access to injectan anticoagulant or an antibacterial agent, so that the anticoagulant or the antibacterial agent is slowly released towards tissues around the compartment and / or the venous port access communicating with the infusion catheter via the diaphragm. The double-compartment venous port access is convenient for surgical implantation, and the venous port access is small in surgical incision and convenientfor puncture and infusion operations; and moreover, risks of thrombus and secondary infection can be effectively reduced.

The invention discloses efficient hemostatic sponge. The efficient hemostatic sponge is prepared from the following raw materials in percentage by mass: 35%-60% of chitosan, 0.1%-0.5% of thrombin, 1%-3% of polyglutamic acid, 9% of sodium chloride, 20%-35% of sodium alginate, 5%-15% of sodium hyaluronate and 1%-5% of calcium chloride. The efficient hemostatic sponge comprises a surface layer and an inner layer, wherein the surface layer is an antibacterial hemostatic layer containing chitosan, thrombin, polyglutamic acid and sodium chloride; and the inner layer is a gel layer containing sodium alginate, sodium hyaluronate and calcium chloride. The inner layer of the hemostatic sponge is in direct contact with a wound and is capable of absorbing moisture in blood to form gel to block the wound so as to realize primary hemostasis; concentrated blood penetrates through the gel layer to enter the surface layer so as to realize further hemostasis with the combined action of thrombin and chitosan; immobilized thrombin on an outer layer in the hemostatic sponge is capable of enhancing the stability, preserves efficient hemostatic activity and is unlikely to enter blood to cause a thrombus risk; and the efficient hemostatic sponge is particularly applicable to rapid hemostasis of serious bleeding caused by deep wounds, arteriorrhexis and the like.

The invention discloses a novel nano fiber vascular stent material with double-drug loading and staged slow release functions and a preparation method thereof. Immunoglobulin lgG antibodies coupled tothe outer layer of the stent material stimulate cells to form epithelial tissues, so that the risk of thrombus formation is reduced; due to decomposition of polylactic acid on the outer layer of thescaffold, penicillin loaded on polylactic acid is slowly released, and division and growth of abnormal cells are inhibited. Due to decomposition of a nitric oxide donor combined with chitosan on the inner layer of the stent, nitric oxide free radicals are slowly released so as to expand blood vessels and inhibit tumor growth. The stent material has double drugs: loaded penicillin and nitric oxideand has a function of slowly releasing drugs in different stages layer by layer; the stent is expected to serve as a novel multifunctional vascular stent in clinic and can be implanted into coronary artery blood vessels of a patient, and multiple postoperative treatment effects of supporting focus blood vessels, reducing thrombus risks, inhibiting cytopathy, expanding blood vessels through free radicals, inhibiting tumor growth and the like are achieved.

The invention discloses a novel nanofiber vascular stent material with dual-drug loading and step-by-step slow-release functions and a preparation method thereof. The immunoglobulin IgG antibody coupled to the outer layer of the stent material stimulates cells to form epithelial tissue and reduces the formation of thrombus risk; due to the decomposition of polylactic acid in the outer layer of the scaffold, the penicillin loaded by it is slowly released, which inhibits the division and growth of abnormal cells; due to the decomposition of the nitric oxide donor bound to chitosan in the inner layer of the scaffold, the nitric oxide is slowly released freely base, to dilate blood vessels and inhibit tumor growth; the scaffold material has the function of loading penicillin and nitric oxide dual drugs, and releases drugs layer by layer, and is expected to be clinically used as a new type of multifunctional vascular stent implanted in the patient's heart Coronary arteries can achieve many postoperative therapeutic effects such as supporting the lesion blood vessels, reducing the risk of thrombus, inhibiting cytopathy, expanding blood vessels by free radicals, and inhibiting tumor growth.

The invention relates to the technical field of medicines and discloses multifunctional bleeding arresting nanoparticles with low thrombosis risk. The multifunctional bleeding arresting nanoparticlesare prepared from the following ingredients in parts by weight: 1-4 parts of polypeptide with positive charges and 2-4 parts of prodrug of antiplatelet drugs. The invention further provides a preparation method for the multifunctional bleeding arresting nanoparticles with low thrombosis risk. The invention further provides application of the multifunctional bleeding arresting nanoparticles with low thrombosis risk. The multifunctional bleeding arresting nanoparticles can be used for efficiently arresting bleeding, resisting infection and promoting restoration and can be used for inhibiting a hypercoagulative state of blood in an organism and lowering the risk of thrombosis.

The invention discloses a medicine for preventing and treating restenosis after coronary artery stent implantation and a preparation method thereof, which comprises the following raw materials in parts by weight: 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of borneol, 6-9 parts of muscone are made into 1000 parts. The invention has the characteristics of good curative effect, no toxic and side effects, can reduce the incidence of restenosis after coronary artery stent implantation, obviously improve the clinical symptoms of patients, reduce the long-term thrombosis risk of patients, and the like, and has remarkable clinical curative effect. It provides a new option for preventing restenosis (ISR) after coronary stent implantation.

The invention belongs to the technical field of polymorphism detection, and particularly relates to a human venous thrombosis risk gene polymorphism detection kit and process and application. PAI-1 4G / 5G and THBDc.-151Ggt are detected at the same time; t, and PROC 565Cgt; the invention discloses a kit for detecting the polymorphism of genes such as T (rs146922325) and PROC c.574576del, the kit comprises a reagent A, a reagent B, a positive quality control A, a positive quality control product B and a negative control, and the reagent A comprises a PAI-1 4G / 5G wild type and THBD c.-151Ggt; a specific primer, a common probe and a paired primer of the T wild type, PROC 565Cgt; t upstream and downstream primers, and PROC 565Cgt; according to the kit, a PCR-fluorescent probe method is adopted, a completely closed system is adopted for amplification reaction and detection, false positive caused by aerosol pollution is avoided, and the kit is simple in operation method, short in detection period, low in detection cost and good in sensitivity and specificity.

The invention discloses a PICC thrombus risk prediction method based on machine learning, and the method comprises the steps: collecting 30 features affecting PICC thrombus of each patient, and carrying out the filling of the missing values of the features; preprocessing the filled features; constructing a plurality of risk prediction models based on machine learning, and respectively calculating an F1 index, an accuracy rate, a recall rate and an AUC of each risk prediction model; determining the effect of each risk prediction model according to the F1 index, the accuracy rate, the recall rate and the AUC of each risk prediction model; selecting two risk prediction models with optimal effects; and based on the AUC values of the two risk prediction models with the optimal effects and the probability of predicting the AUC values to be 1, fusing the two risk prediction models with the optimal effects, and outputting a PICC thrombus risk prediction result. Precise recognition of thrombus occurrence risks is achieved, treatment or nursing measures are taken in advance to conduct medicine or physical intervention on high-risk patients, and therefore the probability of thrombus occurrence of the patients is reduced.